Saturday, April 22, 2006

BUPRENORPHINE, OTP AND OFFICE – BASED TREATMENT OF OPIOID DEPENDENCE
Additional Fees Apply – See Below for Registration Information

TIME: 8:00 AM – 5:30 PM

Course Director:
David Fiellin, MD
Yale University School of Medicine, New Haven, CT

Course Faculty:
Leslie Amass, PhD
Friends Research Institute, Inc., Los Angeles, CA

Ira Marion, MA
Division of Substance Abuse, Albert Einstein College of Medicine, New York, NY

Judith Martin, MD
14th Street Clinic, Oakland, CA

Lynn Sullivan, MD
Yale University School of Medicine, New Haven, CT

The Drug Addiction Treatment Act of 2000 (PL106-310, Section 3502) permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV, or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine sublingual and the combination of buprenorphine/naloxone are approved by FDA for use in detoxification and maintenance treatment of opioid dependence. Physicians are qualified if they are certified in Addiction Medicine or Addiction Psychiatry.

EDUCATIONAL OBJECTIVES:
After participating in this course, you should be able to describe:

• The prerequisites for a physician to begin prescribing buprenorphine in office-based practice
• The clinically relevant pharmacological characteristics of buprenorphine
• Factors to consider in determining if a patient is an appropriate candidate for office-based treatment
• Induction, maintenance, and detoxification protocols
• Strategies for integrating psychosocial care with office-based pharmacological treatment
• Treatment strategies for management of chronic and acute pain in patients in maintenance treatment for opioid dependence
• The appropriate monitoring of patients with HIV and/or HCV who are receiving buprenorphine

PROGRAM TOPICS AND TIME

7:00 AM – 8:00 AM Registration and Mandatory Sign-In
8:00 AM – 5:30 PM Program, Including Lunch

• Overview of Opioid Dependence
• Rationale for Opioid Agonist Treatment
• Legislative Changes Allowing Office-Based Treatment of Opioid
• Dependence, Including the Drug Addiction Treatment Act of 2000
• General Opioid Pharmacology
• Pharmacology of Buprenorphine and Buprenorphine/Naloxone
• Efficacy and Safety of Buprenorphine/Naloxone
• Clinical Use of Buprenorphine and Buprenorphine/Naloxone, Including Induction, Maintenance, and Pharmacologic Withdrawal
• Patient Assessment and Selection
• Office Procedures and Logistics
• Psychiatric Co-Morbidity in Opioid Dependent Patients
• Medical Co-Morbidity in Opioid Dependent Patients
• The Role of Psychosocial Counseling in the Treatment of Opioid Dependence
• Special Treatment Populations, Including the Management of Patients who Develop Pain while Receiving Buprenorphine/Naloxone, Pregnancy and Adolescents

5:30 PM Mandatory Sign-Out

As part of the requirements to obtain the waiver, physicians not otherwise qualified must complete not less than 8 hours of training. Physicians who complete this 8-hour course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of HHS along with the request for the waiver. If you give ASAM permission to do so, ASAM will report your name directly to the Secretary of HHS within 4 weeks of the program, if you have attended the full 8 hours, eliminating the need for you to send the certificate of attendance. Because
ASAM will be called upon to confirm that participants have attended a full 8 hours, you must bring a photo identification to show as part of the sign-in process; you must confirm your attendance with your signature at the beginning of both the morning and the afternoon sessions; and you must sign out at the conclusion of the program.

Sponsored by the American Society of Addiction Medicine.
Supported by an unrestricted continuing medical educational grant provided by Reckitt Benckiser.